

Part

11 腫瘍

第1章 悪性腫瘍（総論）

◎参考文献

1. Choosing Wisely. ASCO. Ten things Physicians and Patients should question. Released April 4, 2012 (1-5) and October 29, 2013 (6-10). <<http://www.choosingwisely.org/societies/american-society-of-clinical-oncology/>>
2. Mohammed N, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011 ; 79 : 466-72.
PMID : 20471184
3. Eisenhauer EA, et al. New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). *Eur J Cancer* 2009 ; 45 : 228-47. PMID : 19097774
4. Clinical Research Resource HUB. Clinical Trial Protocol Development. <<https://hub.ucsf.edu/protocol-development>>
5. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 6. 2015. <https://www.nccn.org/professionals/physician_gls/f_guidelines.asp>
ガイドライン
6. Warr J, et al. Baseline blood work before initiation of chemotherapy : what is safe in the real world? *J Oncol Pract* 2013 ; 9 : e182-5. PMID : 24045345
7. NCCN Clinical Practice Guidelines in Oncology. Older Adult Oncology Version 2. 2015. <https://www.nccn.org/professionals/physician_gls/f_guidelines.asp>
ガイドライン
8. Van Poznak CH, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. *J Clin Oncol* 2011 ; 29 : 1221-7. PMID : 21343561
9. Gardner A, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol* 2008 ; 26 : 5684-8. PMID : 18955453
10. Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014 ; 58 : e44-100. PMID : 24311479
11. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 1. 2015. <https://www.nccn.org/professionals/physician_gls/f_guidelines.asp>
ガイドライン
12. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer Version 1. 2016. <https://www.nccn.org/professionals/physician_gls/f_guidelines.asp>
ガイドライン
13. NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer Version 1. 2016. <https://www.nccn.org/professionals/physician_gls/f_guidelines.asp> **ガイドライン**
14. NCCN Clinical Practice Guidelines in Oncology. Palliative Care Version 1. 2016.

<https://www.nccn.org/professionals/physician_gls/f_guidelines.asp> **ガイドライン**

15. Clarke G, et al. Withdrawal of anticancer therapy in advanced disease : a systematic literature review. BMC Cancer 2015 ; 15 : 892. PMID : 26559912

●参考ウェブサイト

- 日本臨床腫瘍研究グループ (Japan Clinical Oncology Group : JCOG) <<http://www.jcog.jp/>>
- NCCN ガイドライン 日本語版<<http://www.tri-kobe.org/nccn/index.html>>
- NCCN Clinical Practice Guidelines in Oncology <http://www.nccn.org/professionals/physician_gls/f_guidelines.asp>
- ASCO Clinical Practice Guidelines <<http://jco.ascopubs.org/site/misc/specialarticles.xhtml>>
- 日本乳癌学会 <<http://jbcg.gr.jp>>
- 日本肺癌学会 <<https://www.haigan.gr.jp>>
- 日本泌尿器科学会 <<https://www.urol.or.jp>>
- 日本胃癌学会 <<http://www.jgca.jp>>
- 日本膀胱学会 <<http://www.suizou.org>>
- 日本婦人科腫瘍学会 <<https://jsgo.or.jp>>
- 日本癌治療学会 <<http://www.jsco.or.jp/jpn/>>
- 日本臨床腫瘍学会 <<http://www.jsmo.or.jp>>

第2章 悪性腫瘍の緊急症

発熱性好中球減少症

●参照文献

1. 青木 真. レジデントのための感染症診療マニュアル第3版. 東京 : 医学書院. 2015.
2. IDSA Practice Guidelines. <<http://www.idsociety.org/Content.aspx?id=9088>> **ガイドライン**
3. Klastersky J, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006 ; 24 : 4129-34. PMID : 16943529
4. Viscoli C, et al. Infections in patients with febrile neutropenia : epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005 ; 40 : S240-5. PMID : 15768329
5. Mhaskar R, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014 ; (10) : CD003039. PMID : 25356786
6. NCCN Clinical Practice Guidelines in Oncology. Myeloid Growth Factors, version 1. 2015. <http://www.nccn.org/professionals/physician_gls/f_guidelines.asp> **ガイドライン**

●推奨文献

- 日本臨床腫瘍学会. 発熱性好中球減少症診療ガイドライン. 2012. <minds4.jcqh.or.jp/minds/febrile-neutropenia/febrile-neutropenia-front-matter.pdf> **ガイドライン**

脊髄圧迫症候群

◎参照文献

1. Husband DJ. Malignant spinal cord compression : prospective study of delays in referral and treatment. *BMJ* 1998 ; 317 : 18-21. PMID : 9651261
2. Hagenau C, et al. Comparison of spinal magnetic resonance imaging and myelography in cancer patients. *J Clin Oncol* 1987 ; 5 : 1663-9. PMID : 3655863
3. Patchell RA, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer : a randomised trial. *Lancet* 2005 ; 366 : 643-8. PMID : 16112300
4. Graham PH, et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy : TROG 01.05 Superdex study. *Clin Oncol (R Coll Radiol)* 2006 ; 18 : 70-6. PMID : 16477923
5. Vecht CJ, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. *Neurology* 1989 ; 39 : 1255-7. PMID : 2771077

腫瘍崩壊症候群

◎参照文献

1. Cairo MS, et al. Tumour lysis syndrome : new therapeutic strategies and classification. *Br J Haematol* 2004 ; 127 : 3-11. PMID : 15384972
2. Cairo MS, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. *Br J Haematol* 2010 ; 149 : 578-86. PMID : 20331465

◎推奨文献

- Howard SC, et al. The tumor lysis syndrome. *N Engl J Med* 2011 ; 364 : 1844-54. PMID : 21561350
- 日本臨床腫瘍学会. 腫瘍崩壊症候群 (TLS) 診療ガイドランス. 東京 : 金原出版. 2013. [ガイドライン](#)
- Coiffier B, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. *J Clin Oncol* 2008 ; 26 : 2767-78. PMID : 18509186 [ガイドライン](#)
- Jones GL, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol* 2015 ; 169 : 661-71. PMID : 25876990 [ガイドライン](#)

第3章 原発不明がん

◎参照文献

1. Zeller MP, et al. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. *Transfusion* 2016 ; 56 : 73-9. PMID : 26400824
2. Fizazi K, et al. Cancers of unknown primary site : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2011 ; 22 Suppl 6 : vi64-8. PMID : 21908507

3. Pavlidis N, et al. Cancer of unknown primary site. Lancet 2012 ; 379 : 1428-35.
PMID : 22414598
4. Hillen HF. Unknown primary tumours. Postgrad Med J 2000 ; 76 : 690-3.
PMID : 11060142
5. Varadhachary GR, et al. Cancer of unknown primary site. N Engl J Med 2014 ; 371 : 757-65.
PMID : 25140961
6. Moller AK, et al. 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site : a literature review. Oncologist 2011 ; 16 : 445-51.
PMID : 21427201

● 推奨文献

- NCCN Clinical Practice Guidelines in Oncology. Occult Primary<http://www.nccn.org/professionals/physician_gls/f_guidelines.asp>

第4章 悪性腫瘍治療薬の種類と副作用

● 参考文献

1. CTCAE Guideline.<<http://evs.nci.nih.gov/ftp1/CTCAE/About.html>> **ガイドライン**
2. 抗がん剤の副作用と支持療法. 日臨 2015 ; 73. 増刊号 2.
3. Perazella MA. Onco-nephrology : renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012 ; 7 : 1713-21.
PMID : 22879440
4. 日本腎臓学会ほか. がん薬物療法時の腎障害診療ガイドライン 2016.<https://www.jsmo.or.jp/about/doc/guideline_160630.pdf> **ガイドライン**
5. Halyard MY, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer : tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009 ; 27 : 2638-44.
PMID : 19349549
6. Todaro MC, et al. Cardioncology : state of the heart. Int J Cardiol 2013 ; 168 : 680-7.
PMID : 23639459
7. van Dalen EC, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006 ; (4) : CD005008.
PMID : 17054232
8. Smith LA, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer : systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010 ; 10 : 337.
PMID : 20587042
9. NCCN Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. Version 1.1. 2015.<http://www.nccn.org/professionals/physician_gls/f_guidelines.asp> **ガイドライン**
10. NCCN Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy- Induced Anemia. Version 2. 2016.<http://www.nccn.org/professionals/physician_gls/f_guidelines.asp> **ガイドライン**
11. Schiffer CA, et al. Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 ; 19 : 1519-38.
PMID : 11230498
12. 日本肝臓学会. B型肝炎治療ガイドライン第2.2版. 2016年.<https://www.jsh.or.jp/files/uploads/HBV_GL_ver2.2_May30.pdf> **ガイドライン**

13. DeVita, Hellman, and Rosenberg's Cancer : Principles & Practice of Oncology (Cancer Principles and Practice of Oncology), 10th ed. Philadelphia : Lippincott Williams & Wilkins, 2014.
14. Chu E, et al. Physicians' Cancer Chemotherapy Drug Manual 2016. Jones & Bartlett, 2015.
15. Eigentler TK, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016 : 45 : 7-18. PMID : 26922661
16. Spain L, et al. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016 : 44 : 51-60. PMID : 26874776

第5章 がん性疼痛

◎参照文献

1. Stockler M, et al. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen : a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004 : 22 : 3389-94. PMID : 15310785
2. Abernethy AP, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003 : 327 : 523-8. PMID : 12958109
3. Caraceni A, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 : 13 : e58-68. PMID : 22300860 [ガイドライン](#)
4. 日本緩和医療学会. がん疼痛の薬物療法に関するガイドライン (2014年版). 東京 : 金原出版, 2014. <<https://www.jspm.ne.jp/guidelines/pain/2014/index.php>>

[ガイドライン](#)

◎推奨文献

- 木澤義之ほか. 3ステップ実践緩和ケア. 東京 : 青海社, 2013.
- 森田達也. 緩和治療薬の考え方, 使い方. 東京 : 中外医学社, 2014.

第6章 悪心・嘔吐のマネジメント

◎参照文献

1. Quigley EM, et al. AGA technical review on nausea and vomiting. Gastroenterology 2001 : 120 : 263-86. PMID : 11208736
2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008 : 358 : 2482-94. PMID : 18525044
3. Ryken TC, et al. The role of steroids in the management of brain metastases : a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010 : 96 : 103-14. PMID : 19957014
4. 日本癌治療学会. がん診療ガイドライン. 制吐療法. <<http://jsco-cpg.jp/item/29/>>

[ガイドライン](#)

● 推奨文献

- NCCN Guidelines for Antiemesis. <http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf>
- ASCO Guideline, Antiemetics : American Society of Clinical Oncology Clinical Practice Guideline Update. <<http://jco.ascopubs.org/content/29/31/4189.full>>

第7章 腫瘍随伴症候群**● 参照文献**

1. Pelosof LC, et al. Paraneoplastic syndromes : an approach to diagnosis and treatment. Mayo Clin Proc 2010 ; 85 : 838-54. PMID : 20810794
2. Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1135-40. PMID : 15258215
3. Zell JA, et al. Neoplastic fever : a neglected paraneoplastic syndrome. Support Care Cancer 2005 ; 13 : 870-7. PMID : 15864658
4. Cunha BA, et al. Fever of unknown origin : a clinical approach. Am J Med 2015 ; 128 : 1138. e1-1138. e15. PMID : 26093175

● 推奨文献

- 日本臨床腫瘍学会. 新臨床腫瘍学. 改訂第4版. 東京 : 南江堂, 2015.
- 国立がん研究センター内科レジデント. がん診療レジデントマニュアル第7版. 東京 : 医学書院, 2016.